271 related articles for article (PubMed ID: 7831657)
1. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
[TBL] [Abstract][Full Text] [Related]
2. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
3. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
[TBL] [Abstract][Full Text] [Related]
4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
5. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
6. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
[TBL] [Abstract][Full Text] [Related]
7. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery.
Agnelli G; Sonaglia F
Semin Thromb Hemost; 1997; 23(2):143-8. PubMed ID: 9200338
[TBL] [Abstract][Full Text] [Related]
8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
9. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
[TBL] [Abstract][Full Text] [Related]
10. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.
Schiele F; Lindgaerde F; Eriksson H; Bassand JP; Wallmark A; Hansson PO; Grollier G; Sjo M; Moia M; Camez A; Smyth V; Walker M
Thromb Haemost; 1997 May; 77(5):834-8. PubMed ID: 9184388
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
18. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
19. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty.
Cohen AT; Phillips MJ; Edmondson RA; Skinner JA; Das SK; Cooper DJ; Thomas EM; Melissari E; Kakkar VV
Thromb Haemost; 1994 Dec; 72(6):793-8. PubMed ID: 7740443
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
